Collectively, EBAG9 silencing endows BCMA CAR T cells with a considerably improved capacity to reduce tumor growth in vivo, as even low numbers of killing-enhanced CAR T cells gained control over aggressive tumor progression. The gene discussed is EBAG9; the disease is neoplasm.